Blood-based biomarkers to rule out cerebral lesions in mild traumatic brain injuries

San Miguel L, Roberfroid D, Jespers V.
Record ID 32018013263
English
Original Title: Evaluation of novel blood-based brain biomarkers for mild traumatic brain injuries (Study 2023-11)
Authors' results and conclusions: 8.1 Diagnostic Performance Our meta-analyses demonstrated a high sensitivity for the combination of GFAP+UCH-L1 (i.e. 98%) and a great capacity for ruling out ICIs after mTBI. This performance reflects the complementary kinetics of both markers: UCH-L1 peaks soon after trauma, while GFAP rises later, extending the diagnostic window up to 12 hours. This evidence has granted the test FDA approval and appears to be gaining growing clinical endorsement across Europe, as shown in our chapter on the European recommendations. Nevertheless, the test’s low specificity (29%) results in numerous false positives, limiting CT scan reduction. Many patients may still undergo unnecessary imaging and radiation, while increased laboratory testing could add organisational complexity and budgetary impact. Adjusting cut-offs by age, as shown by Ladang et al. (2024), may significantly improve accuracy and reduce unnecessary CT scans in this population. Nevertheless, further validation is still needed in this regard. Paediatric studies remain scarce, though the high sensitivity observed suggests potential utility if restricted to cases where CT would otherwise be performed. New studies in this specific population are underway (e.g. The BRAINI-2 studycc). Further research should validate whole-blood assays and assess real-world effectiveness comparing standard head-rule based care with biomarker-guided strategies. Comparative and Practical Considerations The diagnostic performance of GFAP+UCH-L1 is comparable to S100β, yet its longer sampling window and independence from skin pigmentation offer practical advantages. Although GFAP alone shows slightly higher specificity, no CE-marked test is currently available, and most experts favour the combined test due to its superior sensitivity, an essential feature in a field where missing ICIs must be avoided. The added value of the GFAP+UCH-L1 combination lies beyond sensitivity in its extended diagnostic window and temporal complementarity. While GFAP is effective in detecting brain injury, it can produce false negatives if measured too soon after trauma, as its concentration only rises several hours post-injury. Conversely, UCH-L1 peaks almost immediately, covering the early time gap and ensuring high accuracy across a broader post-injury interval. Similarly, while S100β is reliable within six hours of trauma, its effectiveness decreases sharply thereafter. Therefore, the combination of GFAP and UCH-L1 provides EDs with a more reliable and flexible tool, particularly when the exact timing of injury or sample collection is uncertain. 8.2 Economic and Implementation Evidence The existing economic evaluations are limited as they rely on simplified, assumption-driven models that do not accurately reflect real-world clinical pathways or system-level differences. As such, cost- effectiveness in the Belgian context remains uncertain, highlighting the need for an economic assessment informed by local data. It is important to note that our review identified an abstract of a Belgian economic evaluation in this field, and the first author has confirmed that it will be published in full very soon. 8.3 European recommendations Recommendations that support the use of biomarkers in this field emphasise that they should complement, rather than replace, clinical decision rules. They also acknowledge that, despite promising evidence, uncertainties remain regarding clinical integration, cost and implementation. 8.4 Insights from Belgian Practice While the Belgian expert survey provided useful insight into the current management of mTBI, it must be interpreted with caution. Participation was voluntary and self-reported, which introduced potential selection and reporting biases. The response rate was modest at 32%, with fewer than half of respondents able to provide quantitative data on mTBI management due mainly to the absence of national or local registries and standardised reporting systems. Consequently, the findings may not fully reflect real clinical practices. The absence of mTBI case registration in Belgian administrative databases prevented a data-driven analysis, necessitating reliance on the survey despite its limitations. Nevertheless, the results highlight significant variations in practices, particularly with regard to CT use, influenced by internal protocols, differences in the adoption of clinical head rules, patient characteristics, and medico-legal factors. The use of biomarkers appears to remain negligible, mainly due to limited awareness, reimbursement issues and workflow constraints. Clinicians primarily valued biomarkers that were highly sensitive, had a rapid turnaround time and were affordable, considering them most useful in ambiguous cases or when access to CT or radiation exposure were a concern. 8.5 Outlook and Future Directions GFAP+UCH-L1 testing should be considered an additional tool for clinical decision-making, particularly when a decision about the need for a CT scan is uncertain, delayed or undesirable. Further research should refine population-specific thresholds, validate whole-blood point-of-care testing and evaluate real-world cost-effectiveness. These biomarkers are also being studied as prognostic tools beyond triage, but such use is beyond the scope of this report
Details
Project Status: Completed
Year Published: 2026
URL for published report: https://doi.org/10.57598/R415C
English language abstract: An English language summary is available
Publication Type: Rapid Review
Country: Belgium
MeSH Terms
  • Biomarkers
  • Brain Injuries, Traumatic
  • Hematologic Tests
  • Brain Concussion
Keywords
  • Biomarkers
  • Diagnostic Tests
  • Brain Injuries Traumatic
Contact
Organisation Name: Belgian Health Care Knowledge Centre
Contact Address: 5 Avenue Galilée, PO Box 7, 1210 Brussels. , Belgium
Contact Name: info@kce.fgov.be
Contact Email: info@kce.fgov.be
Copyright: Belgian Health Care Knowledge Centre (KCE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.